When compared with those with KRAS(-)/pMMR tumors, patients with KRAS(+)/pMMR tumors were most likely to be female (49.0% vs 36.0%; OR = 1.85; 95% CI = 1.39 to 2.46; P < 0.0001), to be proximal located (45.5% vs 29.3%; OR = 2.00; 95% CI = 1.30 to 3.08; P = 0.002), to have a mucinous histology (38.4% vs 29.4%; OR = 1.50; 95% CI = 1.11 to 2.01; P = 0.007), and to have increased lymph node metastasis (60.3% vs 50.7%; OR = 1.48; 95% CI = 1.11 to 1.96; P = 0.007) (Table 3). The gene discussed is KRAS; the disease is metastatic malignant neoplasm in the lymph nodes.